Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gen1160
- Development stage
- Unknown
- Lead developer
- Genmab
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
GEN1160 is an antibody-drug conjugate (ADC) designed to target CD70, a protein aberrantly overexpressed in multiple hematologic malignancies and carcinomas, with limited normal tissue expression. The ADC consists of an anti-CD70 monoclonal antibody conjugated to a cytotoxic payload that inhibits DNA topoisomerase I (TOP1), enabling targeted delivery to CD70-expressing cancer cells. Its mechanism aims to induce selective cancer cell killing and minimize off-target toxicity compared to traditional chemotherapies. GEN1160 is undergoing Phase 1/2 clinical trials for advanced solid tumors and hematologic malignancies, including metastatic renal cell carcinoma, non-Hodgkin lymphoma (notably diffuse large B-cell lymphoma and mantle-cell lymphoma), and nasopharyngeal carcinoma[1][2][3][5][6][7][8][9][10]. The primary route of administration is intravenous infusion[9]. Developers include Genmab, a biotechnology company; ProfoundBio is listed as the sponsor for several trials[2][5].
- Brand names
- GEN1160GEN-1160GEN 1160
- Other names
- GEN1160GEN-1160GEN 1160PRO1160PRO-1160PRO 1160
02
Targets
CD70 (Cluster of Differentiation 70)TOP1 (DNA Topoisomerase I)
Beyond the preview
Go deeper on gen1160.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gen1160.